Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research highlights that while JAK inhibitors are effective for various inflammatory conditions, studies raise concerns about increased risks of venous and arterial thromboembolism, and cancer, particularly with tofacitinib and baricitinib, leading to European guidelines recommending caution in high-risk patients.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This case report suggests that Rituximab and high-dose immunosuppressive therapy may be effective for treating severe cutaneous lupus erythematosus like TEN-like ACLE, leading to remission and recovery.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.

This case report describes a patient with both rheumatoid arthritis and alopecia areata who showed improvement in both conditions after treatment with baricitinib monotherapy, highlighting the importance of personalized treatment approaches in managing co-occurring autoimmune diseases.

This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This study suggests that cedrol may improve mitochondrial function, gut microbiota, and intestinal barrier integrity, indicating its potential value in treating inflammatory bowel disease.

This paper argues that for lupus management, selective immunotherapies like anifrolumab and belimumab, which specifically target parts of the immune system, offer more effective treatment options compared to older, broad immunosuppressive strategies.

In this study, adult hereditary angioedema patients treated with lanadelumab at a Spanish hospital had a 94.1% reduction in angioedema episodes and needed 61% less on-demand medication, showing improved quality of life and minimal adverse effects.

This study identified three Ayurvedic compounds that may serve as potential treatments against the macrolide-resistant enzyme murE of *Tropheryma whipplei*, addressing challenges in treating Whipple disease.

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.

This article reviews systemic lupus erythematosus (SLE) and highlights the FDA approval of belimumab, marking the first new SLE treatment in nearly 50 years, but reports no new clinical trial results.

Abatacept may help some people with alopecia areata regrow hair.

This case report describes a patient who developed severe alopecia and a rash after increasing captopril dosage, which resolved upon discontinuing the medication.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This study observed that while all DMARD regimens had similar safety profiles, the leflunomide group experienced the most serious side effects leading to therapy discontinuation.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This review discusses stem cell therapy as a promising treatment for epidermolysis bullosa, highlighting preliminary successes in treating skin lesions but noting the need for further research on effectiveness and safety.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.